drugset / Trial / NCT00216580

A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis

NCT00216580

Phase 3 Completed 50 enrolled Janssen Pharmaceutica N.V., Belgium
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the effectiveness and safety of long-acting injectable risperidone in the treatment of patients in the early stage of psychosis

Timeline

Start
2004-02
Primary completion
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 25 mg
Subject Risperidone Other / unclassified 37.5 mg
Subject Risperidone Other / unclassified 50 mg

Indications